BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 466-467

  Hirbe, Angela C ^a   Pekmezci, Melike ^b   Dahiya, Sonika ^c   Apicelli, Anthony J ^c   Van Tine, Brian A ^a   Perry, Arie ^b   Gutmann, David H ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

microarray; MPNST; NF1; sarcoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GENETICS; HUMAN; LETTER; MALE; MICROARRAY; MIDDLE AGED; MORTALITY; MPNST; MUTATION; NEURILEMOMA; NEUROFIBROMATOSIS; NF1; SARCOMA; SECOND CANCER; VERY ELDERLY; YOUNG ADULT;

MICROARRAY; MPNST; NF1; SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, SECOND PRIMARY; NEURILEMMOMA; NEUROFIBROMATOSIS 1; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84894243342     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not248     Document Type: Letter

References (15)

1. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008;19:533-543.
2. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124-133.
3. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-715.
4. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69:265-273.
5. Dienstmann R, Tabernero J. BRAF as a target for cancer therapy. Anticancer Agents Med Chem. 2011;11:285-295.
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
7. Dahiya S, Haydon DH, Alvarado D, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013;125:901-910.
8. ColombaE, Helias-Rodzewicz Z,VonDeimling A, et al. Detection ofBRAF p.V600Emutations inmelanomas: comparison of fourmethods argues for sequential use of immunohistochemistry and pyrosequencing.JMol Diagn. 2013;15:94-100.
9. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
10. DucatmanBS, ScheithauerBW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006-2021.
11. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573-1577.
12. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39: 311-314.
13. Serrano C, Simonetti S, Hernandez-Losa J, et al. BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours. Histopathology. 2013;62:499-504.
14. Dahiya S, Haydon DH, Leonard JR, et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol. 2014;16:318-319.
15. Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, et al.BRAFduplicationsand MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol. 2012;71:789-794.